entertainment -WSS

entertainment

author：focus 2025-08-10 11:42:25 - browse：15597

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Solve the antibiotic resistance crisis with preventive drugs

WSS

FDA warns J&J's Abiomed: We will regulate your software

For Medicare Advantage, Democrats want stronger protections around AI

Senate committee scrutinizes Medicare Advantage brokers

KalVista pill reduced swelling 'attacks' caused by genetic disease

The explosion of genetic testing requires a new approach

KalVista pill reduced swelling 'attacks' caused by genetic disease

leisure time

entertainment

focus

Peter Hotez and the public health issue of online harassment

Studies point to risks of excluding people with obesity from drug trials

23andMe had bad news about my health. I wish a person had delivered it

A disappointing year of Humira biosimilars

Trump demands the U.S. pay no more for drugs than other countries … again

Why did Pfizer dish out millions for a Super Bowl ad?

Cancer drug shortages should be causing more outrage

KalVista pill reduced swelling 'attacks' caused by genetic disease

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

PhRMA lawsuit over Medicare drug price negotiation tossed

focus

Researchers explore possible ties between long Covid, menopause

BioAge raises $170M for combination therapy with Zepbound

The Readout: Gilead, Bernie Sanders, and other pharma news

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

UnitedHealth’s board chair also owns a personal investment firm

KalVista pill reduced swelling 'attacks' caused by genetic disease

leisure time

focus

leisure time

Wikipedia